Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
25 avr. 2024 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
Gene Therapy For Ocular Rare Disease Pipeline Insight Report 2024
25 avr. 2024 04h06 HE
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy For Ocular Rare Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.The report provides...
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting
23 avr. 2024 08h09 HE
|
Sania Therapeutics
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting Abstracts outline an approach which is highly translatable,...
U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline and Growing Prevalence of Target Diseases Fueling Growth and Developments
23 avr. 2024 05h46 HE
|
Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "U.S. Gene Therapy Market Size, Share & Trends Analysis Report by Indication (Multiple Myeloma, Spinal Muscular Atrophy, Inherited Retinal...
Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded
22 avr. 2024 15h29 HE
|
King Faisal Foundation
Riyadh, Saudi Arabia, April 22, 2024 (GLOBE NEWSWIRE) -- During the 46th session of King Faisal Prize on April 22, exceptional accomplishments in the fields of gene therapy for neuromuscular...
Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs
19 avr. 2024 07h35 HE
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Natural Killer (NK) cell therapy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Natural Killer...
AAV Vectors in Gene Therapy Pipeline Landscape Report 2024: Comprehensive Insights about 70+ Companies and 235+ Pipeline Drugs
19 avr. 2024 07h31 HE
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "AAV vectors in gene therapy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "AAV vectors in gene...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
19 avr. 2024 07h13 HE
|
Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
12 avr. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting
11 avr. 2024 07h00 HE
|
Sania Therapeutics
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on...